Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells.
BACKGROUND
Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells AIM: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures.


METHODS
The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array.


RESULTS
Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments.


CONCLUSIONS
This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
Programa de Pós-Graduação em Genética, Universidade Estadual Paulista 'Júlio de Mesquita Filho' (UNESP/IBILCE), São José do Rio Preto, Brazil.|Faculdade de Medicina de São José do Rio Preto (FAMERP), Laboratório de Investigação Molecular do Câncer (LIMC), São José do Rio Preto, Brazil.
G B
GB
Gelaleti
Georgia Cancer Center, Tumor Imaging Angiogenesis Laboratory, Augusta University, Augusta, Georgia.
T F
TF
Borin
Faculdade de Medicina de São José do Rio Preto (FAMERP), Laboratório de Investigação Molecular do Câncer (LIMC), São José do Rio Preto, Brazil.
L B
LB
Maschio-Signorini
Faculdade de Medicina de São José do Rio Preto (FAMERP), Laboratório de Investigação Molecular do Câncer (LIMC), São José do Rio Preto, Brazil.
M G
MG
Moschetta
Department of Anatomy, Physiology and Biochemistry, Faculty of Veterinary Medicine, Swedish University of Agricultural Sciences, Uppsala, Sweden.
E
E
Hellmén
Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Canada.
A M
AM
Viloria-Petit
Programa de Pós-Graduação em Genética, Universidade Estadual Paulista 'Júlio de Mesquita Filho' (UNESP/IBILCE), São José do Rio Preto, Brazil.|Faculdade de Medicina de São José do Rio Preto (FAMERP), Laboratório de Investigação Molecular do Câncer (LIMC), São José do Rio Preto, Brazil.
D A P C
DAPC
Zuccari
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D005455:Fluorescent Antibody Technique / Q000662:veterinary; D020868:Gene Silencing; D020381:Interleukin-17 / Q000494:pharmacology*; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000473:pathology; D008550:Melatonin / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020381:Interleukin-17; D042461:Vascular Endothelial Growth Factor A; D053148:Caspase 3; D008550:Melatonin
angiogenesis; apoptosis; canine; interleukin-25; mammary tumour cells; melatonin